US-based digital health company Hinge Health has launched Enso 3, a wireless device designed to alleviate musculoskeletal pain and provide immediate relief.
The US Food and Drug Administration (FDA)-cleared Enso 3 delivers electrical nerve stimulation technology, providing rapid, non-invasive, non-addictive pain relief.
Hinge Health added the technology to its portfolio by acquiring medical device company Enso in 2021.
Enso 3 features reimagined hardware with fresh colours, finishes, and materials.
It is small and lightweight and attaches to the skin with a reusable gel pad. This design makes wearing it comfortable before exercise therapy or during daily activities affected by pain.
Enso 3 introduces new electrical waveforms that are tailored for different body parts and pain levels.
These waveforms consist of electrical signals programmed into the device through software to relieve pain.
Additionally, the device now includes two new waveforms that are designed for smaller muscles or those with greater sensitivity.
Enso 3 will also receive new treatments via over-the-air software updates, including future waveforms as they are developed.
Hinge Health CEO and co-founder Daniel Perez said: “Over 100,000 Hinge Health members have benefitted from Enso to date, completing over 3.3 million treatment sessions.
“We’re thrilled to be shipping this unparalleled hardware-software medical solution to Hinge Health members, empowering them with the industry’s most advanced pain relief device that’s seamlessly integrated with the world’s leading exercise therapy programme.”
In a recent randomised controlled trial with 325 participants, Enso demonstrated better pain reduction than a traditional transcutaneous electrical nerve stimulation (TENS) device and exercise therapy alone.
After four weeks, Enso users along with exercise therapy were 2.3 times more likely to experience clinically meaningful pain reduction compared to those using TENS devices.
The device used with exercise therapy from Hinge Health was 2.8 times more likely to achieve meaningful pain relief than exercise therapy alone, the digital health company said.
Furthermore, 48.8% of Enso users saw significant pain improvement.
Initial shipments of the Enso 3 are set to begin this month, with broader availability for all new Hinge Health members scheduled to start in 2025.
Last month, Hinge Health and Midi Health partnered to promote menopause care using the latter’s virtual care clinic.
